Taiwan Advance Bio-Pharmaceutical Inc. announced earnings results for the half year ended June 30, 2021. For the half year, the company announced total revenue was TWD 126.665 million compared to TWD 119.892 million a year ago. Operating loss was TWD 42.241 million compared to TWD 22.665 million a year ago. Net loss was TWD 37.037 million compared to TWD 9.861 million a year ago. Basic loss per share from continuing operations was TWD 0.41 compared to TWD 0.12 a year ago.